Mesoestetic launches reformulated Dermamelan
Spanish cosmeceutical skincare brand Mesoestetic is relaunching its well-known Dermamelan hyperpigmentation treatment with a new look and new additions to the treatment pack after reformulations and the evolution of two patents.
After identifying new molecular targets responsible for hyperpigmentation, the new Dermamelan has been formulated to work effectively and synergistically on the main key targets in the hyperpigmentation process, with a dual correcting and regulating action to both remove existing hyperpigmentation and prevent its reappearance.
Two new patents are behind the reformulation – [SYN]pigmentarget, a combination of three actives at optimum concentrations for a high response to the key pigmentation targets; and melaphenone, the brand’s own molecular design with a 3D conformation to provide a high specificity and safety in inhibiting the tyrosinase enzyme.
Also contributing to the new Dermamelan are two transepidermal vehiculation systems – multilamellar nanovesicles to carry and release actives selectively; and iontophoresis technology to allow the formation of microchannels to improve permeability and ensure the actives reach the optimum position.
Dermamelan is still a two-phase treatment comprising and in-clinic appointment and four-month homecare regime. The medical treatment contains Oil Removing Solution, new formula Dermamelan Mask and brand-new hydrogel Dermamelan Ion Mask. The homecare consists of new formula Dermamelan Treatment, Melan Recovery and Mesoprotech Melan 130 Pigment Control.
